The Long Haul: How Pharma and Healthcare can Thrive in 2023

CMIC will be sponsoring the “The Future of Checkpoint Inhibitors and Immuno-oncology” panel session on January 10 from 1:15-2:15 p.m. Join us for an exciting event!

Keiko Oishi,  President and COO of CMIC HOLDINGS Co., Ltd., will be a keynote speaker at this year’s event!

Ms. Oishi is responsible for group-wide business execution. She received her Master of Science degree from the University of Tokyo. She started her career at Nikkei McGraw-Hill, Inc. in Japan (now renamed Nikkei Business Publications), as a staff writer for Nikkei Biotech, the first Japanese newsletter specializing in biotechnology. Ms. Oishi accumulated her biotechnology industry career through working in Genzyme Japan, Ltd., and Genentech, Ltd., a Japanese Branch of Genentech, Inc. in the U.S.

Ms. Oishi joined CMIC in 1996, as Manager of the Strategy Development Department. Over the past 20 years, she has been responsible for International Business and Corporate Development, covering Japan, Korea, China, Singapore, Taiwan and other regions in Asia Pacific, as well as for International Business Development which function could bring in foreign pharma and biotech companies that are interested in drug development in Japan and Asia, to start their regulatory and clinical activities in the region. With her broad international experience and strong leadership, she continuously leads the company to further globalization.

Visit the event website to learn more and to register:

CMIC Group was founded as the first Contract Research Organization (CRO) in Japan. Now, our 1200+ CRAs and 120+ consultants in Japan and Asia Pacific support global clinical trials in various therapeutic areas. Learn more about our Clinical Trial capabilities here >>